Business Context and Reporting Period
Company: Silo Pharma, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: July 9, 2026
Event Date: July 9, 2026 (Agreement); July 10, 2026 (Closing)
Context: The Company entered into securities purchase agreements for a private placement of equity securities with certain institutional investors.
Key Financial Metrics and Transaction Details
| Item | Details |
|---|---|
| Common Stock Sold | 124,000 shares at $6.452 per share |
| Pre-Funded Warrants | 495,965 warrants at $6.4519 per warrant (exercisable at $0.0001) |
| Series A-3 Warrants | 619,965 warrants (Exercise Price: $6.21; Expiry: 5 years) |
| Series A-4 Warrants | 619,965 warrants (Exercise Price: $6.21; Expiry: 18 months) |
| Placement Agent Warrants | 46,497 warrants (Exercise Price: $8.065) |
| Net Proceeds | Approximately $3.5 million |
| Use of Proceeds | Working capital and general corporate purposes |
Note: The filing does not provide specific revenue, profit, cash flow, margin, or debt figures for the reporting period.
Material Changes and Transaction Structure
- Capital Raise: The Company completed a private placement closing on July 10, 2026, raising approximately $3.5 million in net proceeds.
- Ownership Limits: Purchasers are restricted from exercising warrants if it would result in ownership exceeding 4.99% or 9.99% of outstanding common stock, unless a 61-day notice is provided to increase the limit.
- Registration Rights: The Company agreed to file a resale registration statement within 15 days of the agreement and use best efforts to have it declared effective within 30 days (or 60 days in the event of a full SEC review).
- Compensation: H.C. Wainwright & Co., LLC served as the exclusive placement agent, receiving a 7.5% cash fee, a 1.0% management fee, and warrants covering 7.5% of the aggregate shares placed.
Guidance, Outlook, and Risks
Management Commentary: The Company intends to utilize the net proceeds for working capital and general corporate purposes. No specific financial guidance or operational outlook was provided in this filing.
Risks and Contingencies:
- Dilution: The issuance of shares and warrants may result in significant dilution to existing shareholders.
- Market Conditions: The ability to exercise warrants is subject to beneficial ownership limitations, which may restrict liquidity for investors.
- Regulatory: The transaction relies on exemptions from registration under Section 4(a)(2) of the Securities Act and Regulation D.
Key Facts for Investor Verification
- Verify the exact closing date and final net proceeds received (stated as approx. $3.5 million).
- Confirm the effective date of the Resale Registration Statement to determine the expiration dates of the Series A-3 and A-4 warrants.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants and termination provisions.
- Monitor the Company's capital structure for potential dilution upon the exercise of the 1,735,895 total warrant shares (excluding placement agent warrants).